drugset / Trial / NCT02534480
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
NGP 555 is a small molecule preventative therapy aimed at reducing Alzheimer's disease amyloid buildup by targeting Abeta 42 production.
Timeline
- Start
- 2015-03
- Primary completion
- 2015-10
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NGP 555 | Small molecule | 25 mg | Oral |
| Comparator | NGP 555 | Small molecule | 50 mg | Oral |
| Comparator | NGP 555 | Small molecule | 100 mg | Oral |
| Comparator | NGP 555 | Small molecule | 200 mg | Oral |
| Comparator | NGP 555 | Small molecule | 300 mg | Oral |